BIRC5 and myeloproliferative neoplasm: In a previous study, increased survivin/BIRC5 expression was reported in megakaryocytes from MPN patients (ET, PV, and PMF) compared to healthy donors, which was independent of the presence of JAK2V617F and CALR indel mutations.23